Targeted Therapeutics Report : Oncology

Targeted Oncology Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, and healthcare marketers with a detailed understanding of the economics, technologies, indications, and commercial opportunities for targeted oncology drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Next-generation Therapeutics

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. This report examines the fifty therapeutic drugs and the biomarkers they utilize.

Here is a Small Sample of the Things You Will Learn:

• How many suppliers have approved mAb products indicated for one or more types of lung cancer?
• Who are the API suppliers for the EMA approved version of Adcetris?
• How many approved biosimilars (FDA and/or EMA) are there for trastuzumab?
• What is the number of EMA approved biosimilars for oncology indications?
• Which Daiichi Sankyo facilities in Japan are used for the API and final manufacture of Enhertu?
• How many approved mAbs are indicated for HER2-positive Breast Cancer?
• Which two mAbs indicated for oncology are supplied as lyophilized powders for reconstitution?
• How many approved oncology mAbs target the CD20 antigen?
• Which supplier is the oncology mAb market leader in terms of revenue?